<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title>
<![CDATA[ Press Releases | Liquidia ]]>
</title>
<description>
<![CDATA[ Press Releases | Liquidia ]]>
</description>
<link>https://investors.liquidia.com/investors/press-releases</link>
<image>
<url>https://investors.liquidia.com/sites/g/files/knoqqb61061/files/favicon_0_0.png</url>
<title>Press Releases | Liquidia</title>
<link>https://investors.liquidia.com/investors/press-releases</link>
</image>
<generator>https://rss.app</generator>
<lastBuildDate>Thu, 05 Aug 2021 07:39:07 GMT</lastBuildDate>
<atom:link href="https://rss.app/feeds/1MQYiU5WQ1tKLavy.xml" rel="self" type="application/rss+xml"/>
<language>
<![CDATA[ en ]]>
</language>
<item>
<title>
<![CDATA[ Liquidia Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration ]]>
</title>
<description>
<![CDATA[ <div>Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenous MORRISVILLE, N.C. , May 24, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic</div> ]]>
</description>
<link>https://investors.liquidia.com/news-releases/news-release-details/liquidia-announces-generic-treprostinil-injection-now-also</link>
<guid isPermaLink="false">ee0e53d1c0b7f3243b5406e6ea0c4374</guid>
<dc:creator>
<![CDATA[ investors.liquidia.com ]]>
</dc:creator>
<pubDate>Thu, 05 Aug 2021 07:38:58 GMT</pubDate>
</item>
<item>
<title>
<![CDATA[ Liquidia to Report Second Quarter 2021 Financial Results on August 10, 2021 ]]>
</title>
<description>
<![CDATA[ <div>MORRISVILLE, N.C. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2021 financial results on Tuesday, August 10, 2021 . The company will host a webcast and conference call at 8:30 a.m.</div> ]]>
</description>
<link>https://investors.liquidia.com/news-releases/news-release-details/liquidia-report-second-quarter-2021-financial-results-august-10</link>
<guid isPermaLink="false">9cb40bb5cd3ad6746a2ff97e294d62b2</guid>
<dc:creator>
<![CDATA[ investors.liquidia.com ]]>
</dc:creator>
<pubDate>Tue, 03 Aug 2021 12:00:00 GMT</pubDate>
</item>
<item>
<title>
<![CDATA[ Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder ]]>
</title>
<description>
<![CDATA[ <div>MORRISVILLE, N.C. , June 02, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension</div> ]]>
</description>
<link>https://investors.liquidia.com/news-releases/news-release-details/liquidia-announces-fda-acceptance-new-drug-application</link>
<guid isPermaLink="false">2a381830de068cca5c9c4870165e9156</guid>
<dc:creator>
<![CDATA[ investors.liquidia.com ]]>
</dc:creator>
<pubDate>Wed, 02 Jun 2021 12:00:00 GMT</pubDate>
</item>
<item>
<title>
<![CDATA[ Liquidia Corporation To Present At The Jefferies Virtual Healthcare Conference ]]>
</title>
<description>
<![CDATA[ <div>MORRISVILLE, N.C. , May 26, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Damian deGoa, Chief Executive Officer of Liquidia , will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Healthcare</div> ]]>
</description>
<link>https://investors.liquidia.com/news-releases/news-release-details/liquidia-corporation-present-jefferies-virtual-healthcare</link>
<guid isPermaLink="false">19c8ea19dced733fa50b9c6e23a84f04</guid>
<dc:creator>
<![CDATA[ investors.liquidia.com ]]>
</dc:creator>
<pubDate>Wed, 26 May 2021 12:00:00 GMT</pubDate>
</item>
<item>
<title>
<![CDATA[ Liquidia Reports First Quarter 2021 Financial Results and Provides Corporate Update ]]>
</title>
<description>
<![CDATA[ <div>- Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery - Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder - Improved financial position with private placement and access to new credit facility - Company to host webcast and conference</div> ]]>
</description>
<link>https://investors.liquidia.com/news-releases/news-release-details/liquidia-reports-first-quarter-2021-financial-results-and</link>
<guid isPermaLink="false">68d8d76eb4e1c9404108d4727bab327a</guid>
<dc:creator>
<![CDATA[ investors.liquidia.com ]]>
</dc:creator>
<pubDate>Thu, 13 May 2021 12:00:00 GMT</pubDate>
</item>
</channel>
</rss>
